The Purpose of This Study is to Determine the Safety, Tolerability, and Pharmacokinetics of Brexpiprazole Long-acting Injection Following a Single Administration in Healthy Subjects/Patients With Schizophrenia.
A Phase I Clinical Study of the Safety, Tolerability, and Pharmacokinetics of a Single Dose of Brexpiprazole Long-acting Injection in Healthy Subjects/Patients With Schizophrenia.
Sponsor: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
This PHASE1 trial investigates Schizophrenia Disorders and is currently actively recruiting participants. Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. leads this study, which shows 2 recorded versions since 2024 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.
Status Flow
Change History
2 versions recorded-
Dec 2025 — Present [monthly]
Recruiting PHASE1
-
Dec 2024 — Dec 2025 [monthly]
Recruiting PHASE1
First recorded
Apr 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .